Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Other Non-Current Assets data on file, last reported at $28.8 million in Q4 2025.

• Other Non-Current Assets for Q4 2025 came in at $28.8 million, up 79.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $28.8 million (up 79.31% YoY), and the FY2025 annual result was $28.8 million, up 91.0% from the prior year.
• Other Non-Current Assets climbed to $28.8 million in Q4 2025 per TLX's latest filing, from $16.1 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $28.8 million in Q4 2025 and troughed at $381480.4 in Q4 2023.
• A 3-year average of $15.1 million and a median of $16.1 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 4113.99% in 2024, then surged 79.31% in 2025.
• A 3-year view of Other Non-Current Assets shows it stood at $381480.4 in 2023, then soared by 4113.99% to $16.1 million in 2024, then surged by 79.31% to $28.8 million in 2025.
• Business Quant data shows TLX's Other Non-Current Assets at $28.8 million in Q4 2025, $16.1 million in Q4 2024, and $381480.4 in Q4 2023.